ASO Author Reflections: Pancreatic Cancer Patients with Germline BRCA Mutations Benefit from Early Introduction of Platinum-Based Chemotherapy

Annals of Surgical Oncology volume 27, pages3971–3972(2020)Cite this article

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant access to the full article PDF.

US$ 39.95

Tax calculation will be finalised during checkout.

References

  1. 1.

    Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395–2406.

    CAS  Article  Google Scholar 

  2. 2.

    Barenboim A, Lahat G, Geva R, et al. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis. Eur J Surg Oncol. 2018;44:1619–1623.

    Article  Google Scholar 

  3. 3.

    Janssen QP, Buettner S, Suker M, et al. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. J Natl Cancer Inst. 2019;111:782–794.

    Article  Google Scholar 

  4. 4.

    Golan T, Barenboim A, Lahat G, et al. Increased rate of complete pathological response following neoadjuvant FOLFIRINOX in BRCA mutation carriers with borderline resectable pancreatic cancer. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08469-8.

    Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

  1. Institute of Oncology, Sheba Medical Center, Tel Hashomer, Israel

    Talia Golan

  2. Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel

    Talia Golan, Alex Barenboim & Nir Lubezky

  3. Department of Surgery, Tel-Aviv Medical Center, Tel Aviv, Israel

    Alex Barenboim & Nir Lubezky

Authors
  1. Talia Golan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alex Barenboim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nir Lubezky
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Talia Golan: receipt of grants/research supports: Astra Zeneca and MSD Merck; receipt of consultation fees: Abbvie, Astra Zeneca, Teva. Bayer, and MSD Merck; receipt of speakers bureau: Abbvie and Bioline; travel: Astra Zeneca and MSD Merck.

Corresponding author

Correspondence to Nir Lubezky.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Golan, T., Barenboim, A. & Lubezky, N. ASO Author Reflections: Pancreatic Cancer Patients with Germline BRCA Mutations Benefit from Early Introduction of Platinum-Based Chemotherapy. Ann Surg Oncol 27, 3971–3972 (2020). https://doi.org/10.1245/s10434-020-08495-6

Download citation